Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Sher
G D
GD
Bartfay
W J
WJ
Liu
P P
PP
Lehotay
D C
DC
D000447:Aldehydes / Q000097:blood*; D015415:Biomarkers; D015913:Chelation Therapy; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D005609:Free Radicals; D006801:Humans; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000097:blood* / Q000209:etiology / Q000517:prevention & control; D015227:Lipid Peroxidation; D010865:Pilot Projects; D011728:Pyridones / Q000627:therapeutic use; D014168:Transferrin / Q000032:analysis; D017086:beta-Thalassemia / Q000097:blood / Q000628:therapy*
D000447:Aldehydes; D015415:Biomarkers; D005609:Free Radicals; D007502:Iron Chelating Agents; D011728:Pyridones; D014168:Transferrin; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine